Calcium, Phosphorus, and Magnesium Disorders and Stones
8 cases on pharmacologic decisions in mineral bone disease and nephrolithiasis — phosphate binder and vitamin D analog selection, calcimimetic therapy, parathyroidectomy timing, stone-specific medical therapy, and correcting refractory electrolyte disturbance — choose a case below to open its full multi-voice debate.
A hemodialysis patient whose phosphate keeps climbing despite genuine dietary effort, and whose own coronary calcium score may be telling the group which binder class is actually safe for him.
A dialysis patient's parathyroid hormone is climbing toward a level that demands vitamin D therapy, but her calcium is already close enough to the ceiling that the choice of analog itself becomes the argument.
A dialysis patient whose severe hyperparathyroidism has already outlasted one honest attempt at an oral calcimimetic, forcing a real choice between fixing adherence and changing the route entirely.
Three years after a living-donor transplant, a patient's calcium has stayed high on maximal cinacalcet — the question is whether that ceiling has genuinely been reached, or whether one more step in imaging and medical therapy is still owed before surgery.
A recurrent stone former with hypercalciuria and low urinary citrate, and a decades-old thiazide recommendation that a large recent trial just failed to reproduce.
A pure uric acid stone is the one kind that can genuinely dissolve with medication alone — the real question is whether an obstructing stone with mild hydronephrosis is still safe to wait on.
A genetic stone former whose fluid intake and urine logs already look close to ideal, and a question about whether the gap is really conservative therapy failing, or one overnight window it hasn't been reaching.
Two failed rounds of oral magnesium and a new QTc prolongation force a real decision about a drug she's taken for eight years without incident, against a bleed in her history that was genuinely serious.